Clinical Trial Search

Phase 3 N=78 4-drug Nerve Block Versus Plain Local Anesthetic for Knee and Hip Arthroplasty Analgesia in Veterans

Pain

Primary: Short-Form McGill Pain Questionnaire (Version 2) Total Score Difference From Baseline — -1.85; -0.05 score on a scale — p=0.003

Brian Williams Results Dec 2021 0.0% serious AE View details

Phase 3 N=631 Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

Atopic Dermatitis

Primary: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 — 15.1; 50.0; 53.8 percentage of participants — p=< 0.0001

Incyte Corporation Results Dec 2021 2.3% serious AE View details

Phase 3 N=618 TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

Atopic Dermatitis

Primary: VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 — 7.6; 39.0; 51.3 percentage of participants…

Incyte Corporation Results Dec 2021 1.7% serious AE View details

Phase 3 N=829 Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)

COVID-19 · Corona Virus Infection · SARS (Severe Acute Respiratory Syndrome)

Primary: Number of Participants Who Had Polymerase Chain Reaction (PCR) Confirmed SARS-CoV-2 Infection — 45; 53 Participants

University of Washington Results Dec 2021 0.5% serious AE View details

Phase 3 N=256 Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Disorder Related to Bone Marrow Transplantation · Leukemia · Transplantation Infection

Primary: Progression-Free Survival (PFS) — 69; 61 Number of events

M.D. Anderson Cancer Center Results Dec 2021 25.6% serious AE View details

Phase 3 N=372 PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Primary: Analysis of Serum AUC0-last of Rituximab During the 1st Course of the Main Study Period (Over the First 24 Weeks) (ANCOVA) — 162414.81; 167309.07; 172450.97 h*μg/mL

Celltrion Results Dec 2021 5.4% serious AE View details

Phase 3 N=1 A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression

Postpartum Depression

Primary: Parts A and B: Change From Baseline in the 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15 — -13.6; -17.8 score on a scale — p=0.0028

Biogen Results Dec 2021 1.3% serious AE View details

Phase 3 N=372 A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea

Papulopustular Rosacea

Primary: Percentage of Participants Achieving an IGA Score of Clear or Almost Clear From Baseline at Week 12 — 50.1; 25.9 Percentage of Participants

Sol-Gel Technologies, Ltd. Results Dec 2021 0.3% serious AE View details

Phase 3 N=233 Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)

Nasopharyngeal Neoplasms

Primary: Overall Survival (OS) — 17.2; 15.3 Months — p=0.2262

Merck Sharp & Dohme LLC Results Dec 2021 35.6% serious AE View details

Phase 3 N=688 A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone

Metastatic Castration Resistant Prostate Cancer

Primary: Progression Free Survival (PFS) — 9.53; 8.28 months — p=0.027

Astellas Pharma Europe Ltd. Results Dec 2021 37.3% serious AE View details

Phase 3 N=47 Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris

Acne Vulgaris

Primary: Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 12 and 24 — -1.8; -0.5 score on a scale

Galderma R&D Results Dec 2021 0.0% serious AE View details

Phase 3 N=388 PALISADE Follow-on Study (ARC004)

Peanut Allergy

Primary: Percentage of Subjects Ages 4-17 With Treatment-related Adverse Events (TEAE) — 98; 90; 36; 27 Participants

Aimmune Therapeutics, Inc. Results Dec 2021 1.1% serious AE View details

Phase 3 N=262 Cantharidin Application in Molluscum Patients

Molluscum Contagiosum

Primary: Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS) — 81; 15 Participants

Verrica Pharmaceuticals Inc. Results Dec 2021 0.0% serious AE View details

Phase 3 N=118 Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)

Conjunctivitis, Vernal

Primary: Overall Rating of Subjective Symptoms of VKC in Period I — 7; 1; 4; 5 Participants — p=0.2699

Santen SAS Results Dec 2021 0.4% serious AE View details

Phase 3 N=266 Cantharidin Application in Molluscum Patients-1

Molluscum Contagiosum

Primary: Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS) — 74; 19 Participants — p=<0.0001

Verrica Pharmaceuticals Inc. Results Dec 2021 0.4% serious AE View details